ChromaDex To Present At The 26th Annual ROTH Conference On March 10th At 4:30 pm PDT

Irvine, CA /PRNewswire/ -- ChromaDex Corp.^® (OTCQB: CDXC), an innovative natural products company that provides proprietary, ingredients and science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries, announced today that its CEO, Frank Jaksch, will present at the 26th Annual ROTH Conference, which will take place from March 9-12 at the Ritz-Carlton Laguna Niguel in Dana Point, Calif. 

Mr. Jaksch will present on Monday, March 10, at 4:30 p.m. Pacific Time, in addition to meeting one-on-one with institutional investors throughout the day.

The presentation will be webcast live and available for replay at:http://wsw.com/webcast/roth28/cdxc, as well as via the Investors section of the company's website at:
http://investors.chromadex.com/phoenix.zhtml?c=212121&p=irol-investorKit

For more information about the conference or to schedule a one-on-one meeting with Frank Jaksch, please contact your ROTH representative at 1-800-933-6830 or via e-mail at conference@roth.com.

About ChromaDex^®:
ChromaDex® is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model that utilizes its wholly owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services, and product regulatory and safety consulting (as Spherix Consulting). The company provides seamless science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic and pharmaceutical industries. The ChromaDex ingredient technologies unit includes products backed with extensive scientific research and intellectual property. Its ingredient portfolio includes pTeroPure® pterostilbene; ProC3G™, a natural black rice containing cyanidin-3-glucoside;PURENERGY™, a caffeine-pTeroPure co-crystal; and NIAGEN™, its recently launched branded nicotinamide riboside, a novel next-generation B vitamin. To learn more about ChromaDex, visit www.chromadex.com.

Forward-Looking Statements:
Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.